Literature DB >> 27958293

Small-cell lung cancer in 2016: Shining light on novel targets and therapies.

Charles M Rudin1, John T Poirier1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27958293     DOI: 10.1038/nrclinonc.2016.203

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Authors:  Laura R Saunders; Alexander J Bankovich; Wade C Anderson; Monette A Aujay; Sheila Bheddah; KristenAnn Black; Radhika Desai; Paul A Escarpe; Johannes Hampl; Amy Laysang; David Liu; Javier Lopez-Molina; Milly Milton; Albert Park; Marybeth A Pysz; Hui Shao; Brian Slingerland; Michael Torgov; Samuel A Williams; Orit Foord; Philip Howard; Jacek Jassem; Andrzej Badzio; Piotr Czapiewski; David H Harpole; Afshin Dowlati; Pierre P Massion; William D Travis; M Catherine Pietanza; J T Poirier; Charles M Rudin; Robert A Stull; Scott J Dylla
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

2.  Nuclear factor I/B is an oncogene in small cell lung cancer.

Authors:  Alison L Dooley; Monte M Winslow; Derek Y Chiang; Shantanu Banerji; Nicolas Stransky; Talya L Dayton; Eric L Snyder; Stephanie Senna; Charles A Whittaker; Roderick T Bronson; Denise Crowley; Jordi Barretina; Levi Garraway; Matthew Meyerson; Tyler Jacks
Journal:  Genes Dev       Date:  2011-07-15       Impact factor: 11.361

3.  Comprehensive genomic profiles of small cell lung cancer.

Authors:  Julie George; Jing Shan Lim; Se Jin Jang; Yupeng Cun; Luka Ozretić; Gu Kong; Frauke Leenders; Xin Lu; Lynnette Fernández-Cuesta; Graziella Bosco; Christian Müller; Ilona Dahmen; Nadine S Jahchan; Kwon-Sik Park; Dian Yang; Anthony N Karnezis; Dedeepya Vaka; Angela Torres; Maia Segura Wang; Jan O Korbel; Roopika Menon; Sung-Min Chun; Deokhoon Kim; Matt Wilkerson; Neil Hayes; David Engelmann; Brigitte Pützer; Marc Bos; Sebastian Michels; Ignacija Vlasic; Danila Seidel; Berit Pinther; Philipp Schaub; Christian Becker; Janine Altmüller; Jun Yokota; Takashi Kohno; Reika Iwakawa; Koji Tsuta; Masayuki Noguchi; Thomas Muley; Hans Hoffmann; Philipp A Schnabel; Iver Petersen; Yuan Chen; Alex Soltermann; Verena Tischler; Chang-min Choi; Yong-Hee Kim; Pierre P Massion; Yong Zou; Dragana Jovanovic; Milica Kontic; Gavin M Wright; Prudence A Russell; Benjamin Solomon; Ina Koch; Michael Lindner; Lucia A Muscarella; Annamaria la Torre; John K Field; Marko Jakopovic; Jelena Knezevic; Esmeralda Castaños-Vélez; Luca Roz; Ugo Pastorino; Odd-Terje Brustugun; Marius Lund-Iversen; Erik Thunnissen; Jens Köhler; Martin Schuler; Johan Botling; Martin Sandelin; Montserrat Sanchez-Cespedes; Helga B Salvesen; Viktor Achter; Ulrich Lang; Magdalena Bogus; Peter M Schneider; Thomas Zander; Sascha Ansén; Michael Hallek; Jürgen Wolf; Martin Vingron; Yasushi Yatabe; William D Travis; Peter Nürnberg; Christian Reinhardt; Sven Perner; Lukas Heukamp; Reinhard Büttner; Stefan A Haas; Elisabeth Brambilla; Martin Peifer; Julien Sage; Roman K Thomas
Journal:  Nature       Date:  2015-07-13       Impact factor: 49.962

4.  Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Authors:  Martin Reck; Alexander Luft; Aleksandra Szczesna; Libor Havel; Sang-We Kim; Wallace Akerley; Maria Catherine Pietanza; Yi-Long Wu; Christoph Zielinski; Michael Thomas; Enriqueta Felip; Kathryn Gold; Leora Horn; Joachim Aerts; Kazuhiko Nakagawa; Paul Lorigan; Anne Pieters; Teresa Kong Sanchez; Justin Fairchild; David Spigel
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

5.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

6.  CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Authors:  Kipp Weiskopf; Nadine S Jahchan; Peter J Schnorr; Sandra Cristea; Aaron M Ring; Roy L Maute; Anne K Volkmer; Jens-Peter Volkmer; Jie Liu; Jing Shan Lim; Dian Yang; Garrett Seitz; Thuyen Nguyen; Di Wu; Kevin Jude; Heather Guerston; Amira Barkal; Francesca Trapani; Julie George; John T Poirier; Eric E Gardner; Linde A Miles; Elisa de Stanchina; Shane M Lofgren; Hannes Vogel; Monte M Winslow; Caroline Dive; Roman K Thomas; Charles M Rudin; Matt van de Rijn; Ravindra Majeti; K Christopher Garcia; Irving L Weissman; Julien Sage
Journal:  J Clin Invest       Date:  2016-06-13       Impact factor: 14.808

7.  Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

Authors:  Charles M Rudin; M Catherine Pietanza; Todd M Bauer; Neal Ready; Daniel Morgensztern; Bonnie S Glisson; Lauren A Byers; Melissa L Johnson; Howard A Burris; Francisco Robert; Tae H Han; Sheila Bheddah; Noah Theiss; Sky Watson; Deepan Mathur; Bharathi Vennapusa; Hany Zayed; Satwant Lally; Donald K Strickland; Ramaswamy Govindan; Scott J Dylla; Stanford L Peng; David R Spigel
Journal:  Lancet Oncol       Date:  2016-12-05       Impact factor: 41.316

8.  Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility.

Authors:  Sarah K Denny; Dian Yang; Chen-Hua Chuang; Jennifer J Brady; Jing Shan Lim; Barbara M Grüner; Shin-Heng Chiou; Alicia N Schep; Jessika Baral; Cécile Hamard; Martine Antoine; Marie Wislez; Christina S Kong; Andrew J Connolly; Kwon-Sik Park; Julien Sage; William J Greenleaf; Monte M Winslow
Journal:  Cell       Date:  2016-06-30       Impact factor: 41.582

9.  Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.

Authors:  Ekaterina A Semenova; Min-Chul Kwon; Kim Monkhorst; Ji-Ying Song; Rajith Bhaskaran; Oscar Krijgsman; Thomas Kuilman; Dennis Peters; Wieneke A Buikhuisen; Egbert F Smit; Colin Pritchard; Miranda Cozijnsen; Jan van der Vliet; John Zevenhoven; Jan-Paul Lambooij; Natalie Proost; Erwin van Montfort; Arno Velds; Ivo J Huijbers; Anton Berns
Journal:  Cell Rep       Date:  2016-06-30       Impact factor: 9.423

10.  NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer.

Authors:  Nan Wu; Deshui Jia; Ali H Ibrahim; Cindy J Bachurski; Richard M Gronostajski; David MacPherson
Journal:  Oncotarget       Date:  2016-09-06
  10 in total
  24 in total

1.  High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.

Authors:  Chunyan Wang; Shi Jin; Shanqi Xu; Shoubo Cao
Journal:  Lung       Date:  2020-02-03       Impact factor: 2.584

Review 2.  Small-cell lung cancer: what we know, what we need to know and the path forward.

Authors:  Adi F Gazdar; Paul A Bunn; John D Minna
Journal:  Nat Rev Cancer       Date:  2017-10-27       Impact factor: 60.716

3.  IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.

Authors:  Grazia Carbotti; Amin Reza Nikpoor; Paola Vacca; Rosaria Gangemi; Chiara Giordano; Francesco Campelli; Silvano Ferrini; Marina Fabbi
Journal:  J Exp Clin Cancer Res       Date:  2017-10-11

4.  Adjudin synergizes with paclitaxel and inhibits cell growth and metastasis by regulating the sirtuin 3-Forkhead box O3a axis in human small-cell lung cancer.

Authors:  Xue Wang; Qingyu Zeng; Ziming Li; Xiao Yang; Weiliang Xia; Zhiwei Chen
Journal:  Thorac Cancer       Date:  2019-02-18       Impact factor: 3.500

5.  Soluble fms-like tyrosine kinase-1-enriched exosomes suppress the growth of small cell lung cancer by inhibiting endothelial cell migration.

Authors:  Dexun Hao; Yanshuang Li; Gaofeng Zhao; Mingzhi Zhang
Journal:  Thorac Cancer       Date:  2019-08-23       Impact factor: 3.500

6.  CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.

Authors:  Zhengang Qiu; Weiliang Zhu; Hui Meng; Lihua Tong; Xi Li; Peng Luo; Lilan Yi; Xiaoli Zhang; Linlang Guo; Ting Wei; Jian Zhang
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

7.  Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.

Authors:  Fang Huang; Kenneth E Huffman; Zixi Wang; Xun Wang; Kailong Li; Feng Cai; Chendong Yang; Ling Cai; Terry S Shih; Lauren G Zacharias; Andrew Chung; Qian Yang; Milind D Chalishazar; Abbie S Ireland; C Allison Stewart; Kasey Cargill; Luc Girard; Yi Liu; Min Ni; Jian Xu; Xudong Wu; Hao Zhu; Benjamin Drapkin; Lauren A Byers; Trudy G Oliver; Adi F Gazdar; John D Minna; Ralph J DeBerardinis
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

8.  A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy.

Authors:  Xun Yuan; Zhiqin Zheng; Fangfang Liu; Yuan Gao; Wenhui Zhang; Rossana Berardi; Pranshu Mohindra; Zhengfei Zhu; Jie Lin; Qian Chu
Journal:  Transl Lung Cancer Res       Date:  2021-05

9.  Sodium Valproate Inhibits Small Cell Lung Cancer Tumor Growth on the Chicken Embryo Chorioallantoic Membrane and Reduces the p53 and EZH2 Expression.

Authors:  Lina Šlekienė; Donatas Stakišaitis; Ingrida Balnytė; Angelija Valančiūtė
Journal:  Dose Response       Date:  2018-04-26       Impact factor: 2.658

10.  IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer.

Authors:  Mi-Sook Lee; Kyungsoo Jung; Ji-Young Song; Min-Jung Sung; Sung-Bin Ahn; Boram Lee; Doo-Yi Oh; Yoon-La Choi
Journal:  Mol Ther Oncolytics       Date:  2020-01-10       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.